BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27081088)

  • 1. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
    Fanale D; Amodeo V; Bazan V; Insalaco L; Incorvaia L; Barraco N; Castiglia M; Rizzo S; Santini D; Giordano A; Castorina S; Russo A
    Oncotarget; 2016 May; 7(20):29321-32. PubMed ID: 27081088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.
    Insalaco L; Di Gaudio F; Terrasi M; Amodeo V; Caruso S; Corsini LR; Fanale D; Margarese N; Santini D; Bazan V; Russo A
    J Cell Mol Med; 2012 Sep; 16(9):2186-95. PubMed ID: 22260151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells.
    Lan YC; Chang CL; Sung MT; Yin PH; Hsu CC; Wang KC; Lee HC; Tseng LM; Chi CW
    Anticancer Res; 2013 Sep; 33(9):3807-14. PubMed ID: 24023313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid - a multiplicity of anti-cancer action.
    Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
    Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
    Dedes PG; Gialeli Ch; Tsonis AI; Kanakis I; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2012 Dec; 1820(12):1926-39. PubMed ID: 22884656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
    Espinoza I; Liu H; Busby R; Lupu R
    Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
    Denoyelle C; Hong L; Vannier JP; Soria J; Soria C
    Br J Cancer; 2003 May; 88(10):1631-40. PubMed ID: 12771933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
    Bühler H; Hoberg C; Fakhrian K; Adamietz IA
    In Vivo; 2016 11-12; 30(6):761-768. PubMed ID: 27815459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
    Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
    Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
    Vintonenko N; Jais JP; Kassis N; Abdelkarim M; Perret GY; Lecouvey M; Crepin M; Di Benedetto M
    Mol Pharmacol; 2012 Sep; 82(3):521-8. PubMed ID: 22723339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
    J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
    Labrinidis A; Hay S; Liapis V; Findlay DM; Evdokiou A
    Int J Cancer; 2010 Jul; 127(2):345-54. PubMed ID: 19924813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation.
    Yamada J; Tsuno NH; Kitayama J; Tsuchiya T; Yoneyama S; Asakage M; Okaji Y; Shuno Y; Nishikawa T; Tanaka J; Takahashi K; Nagawa H
    J Surg Res; 2009 Jan; 151(1):115-20. PubMed ID: 18619615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
    Wilson C; Ottewell P; Coleman RE; Holen I
    BMC Cancer; 2015 Feb; 15():55. PubMed ID: 25884855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
    Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
    Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.